We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
Read MoreHide Full Article
Quest Diagnostics Inc.’s (DGX - Free Report) first-quarter 2025 adjusted earnings per share (EPS) of $2.21 beat the Zacks Consensus Estimate by 2.8%. The metric also exceeded the year-ago adjusted figure by 8.3%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).
Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures. GAAP earnings came in at $1.94 per share, up 12.8% from last year’s comparable figure.
DGX shares have gained nearly 6.7% in pre-market trading following the earnings report.
DGX’s Revenues in Detail
Revenues reported in the first quarter rose 12.1% year over year to $2.65 billion. The metric surpassed the Zacks Consensus Estimate by 1.5%.
Diagnostic Information Services revenues in the quarter were up 12.7% on a year-over-year basis to $2.59 billion. This figure also surpassed our model’s projection of $2.53 billion for the first quarter.
Quest Diagnostics Incorporated Price, Consensus and EPS Surprise
Volumes (measured by the number of requisitions) were up 12.5% year over year in the first quarter. Revenue per requisition increased 0.3% year over year.
DGX’s Margin Performance
The cost of services during the reported quarter was $1.79 billion, up 12.2% year over year. The gross profit came in at $863 million, up 11.9% year over year. The gross margin was 32.5%, almost similar to the year-ago quarter’s number.
SG&A expenses were $476 million in the quarter under review, up 8.1% from the first quarter of 2024. The adjusted operating margin of 14.6% represented a 60-basis-point expansion year over year.
DGX’s Liquidity and Financial Health
Quest Diagnostics exited the first quarter of 2025 with cash and cash equivalents of $188 million compared with $549 million at the end of fourth-quarter 2024. The cumulative net cash provided by operating activities at the end of the first quarter of 2025 was $314 million compared with $154 million at the end of the same period last year.
Quest Diagnostics reaffirmed its full-year 2025 revenue outlook, expected in the range of $10.70 billion-$10.85 billion, which indicates a year-over-year increase of 8.4%-9.9%. The Zacks Consensus Estimate is pegged at $10.76 billion.
Adjusted EPS is expected in the range of $9.55-$9.80, also unchanged from the initial projection. The Zacks Consensus Estimate for the metric is pegged at $9.68.
Our View on DGX Stock
Quest Diagnostics ended the first quarter of 2025 on a solid note, with both earnings and revenues beating respective estimates. The top line benefited from a rebound in demand in March, following weather-related disruptions earlier in the quarter. The growth was led by contributions from acquisitions and large enterprise accounts, robust uptake of the advanced diagnostics portfolio and expanded health plan access. Expansion of operating margin in the quarter also bodes well.
DGX’s Zacks Rank & Key Picks
Quest Diagnostics currently carries a Zacks Rank #3 (Hold).
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 70.9%.
Veeva Systems, sporting a Zacks Rank #1 at present, posted fourth-quarter fiscal 2025 adjusted EPS of $1.75, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $720.9 million surpassed the Zacks Consensus Estimate by 3.2%.
VEEV has an estimated long-term earnings growth rate of 26.6% compared with the industry’s 20.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.9%.
Masimo, currently sporting a Zacks Rank #1, reported a fourth-quarter 2024 adjusted EPS of $1.80, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $600.7 million topped the Zacks Consensus Estimate by 0.8%.
MASI has an estimated earnings yield of 3.5% for fiscal 2025 compared with the industry’s 3.6% yield. The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
Quest Diagnostics Inc.’s (DGX - Free Report) first-quarter 2025 adjusted earnings per share (EPS) of $2.21 beat the Zacks Consensus Estimate by 2.8%. The metric also exceeded the year-ago adjusted figure by 8.3%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).
Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures. GAAP earnings came in at $1.94 per share, up 12.8% from last year’s comparable figure.
DGX shares have gained nearly 6.7% in pre-market trading following the earnings report.
DGX’s Revenues in Detail
Revenues reported in the first quarter rose 12.1% year over year to $2.65 billion. The metric surpassed the Zacks Consensus Estimate by 1.5%.
Diagnostic Information Services revenues in the quarter were up 12.7% on a year-over-year basis to $2.59 billion. This figure also surpassed our model’s projection of $2.53 billion for the first quarter.
Quest Diagnostics Incorporated Price, Consensus and EPS Surprise
Quest Diagnostics Incorporated price-consensus-eps-surprise-chart | Quest Diagnostics Incorporated Quote
Volumes (measured by the number of requisitions) were up 12.5% year over year in the first quarter. Revenue per requisition increased 0.3% year over year.
DGX’s Margin Performance
The cost of services during the reported quarter was $1.79 billion, up 12.2% year over year. The gross profit came in at $863 million, up 11.9% year over year. The gross margin was 32.5%, almost similar to the year-ago quarter’s number.
SG&A expenses were $476 million in the quarter under review, up 8.1% from the first quarter of 2024. The adjusted operating margin of 14.6% represented a 60-basis-point expansion year over year.
DGX’s Liquidity and Financial Health
Quest Diagnostics exited the first quarter of 2025 with cash and cash equivalents of $188 million compared with $549 million at the end of fourth-quarter 2024. The cumulative net cash provided by operating activities at the end of the first quarter of 2025 was $314 million compared with $154 million at the end of the same period last year.
The company has a five-year annualized dividendgrowth rate of 7.17%.
DGX’s 2025 Guidance
Quest Diagnostics reaffirmed its full-year 2025 revenue outlook, expected in the range of $10.70 billion-$10.85 billion, which indicates a year-over-year increase of 8.4%-9.9%. The Zacks Consensus Estimate is pegged at $10.76 billion.
Adjusted EPS is expected in the range of $9.55-$9.80, also unchanged from the initial projection. The Zacks Consensus Estimate for the metric is pegged at $9.68.
Our View on DGX Stock
Quest Diagnostics ended the first quarter of 2025 on a solid note, with both earnings and revenues beating respective estimates. The top line benefited from a rebound in demand in March, following weather-related disruptions earlier in the quarter. The growth was led by contributions from acquisitions and large enterprise accounts, robust uptake of the advanced diagnostics portfolio and expanded health plan access. Expansion of operating margin in the quarter also bodes well.
DGX’s Zacks Rank & Key Picks
Quest Diagnostics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are AngioDynamics (ANGO - Free Report) , Veeva Systems (VEEV - Free Report) and Masimo (MASI - Free Report) .
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 70.9%.
Veeva Systems, sporting a Zacks Rank #1 at present, posted fourth-quarter fiscal 2025 adjusted EPS of $1.75, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $720.9 million surpassed the Zacks Consensus Estimate by 3.2%.
VEEV has an estimated long-term earnings growth rate of 26.6% compared with the industry’s 20.8% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.9%.
Masimo, currently sporting a Zacks Rank #1, reported a fourth-quarter 2024 adjusted EPS of $1.80, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $600.7 million topped the Zacks Consensus Estimate by 0.8%.
MASI has an estimated earnings yield of 3.5% for fiscal 2025 compared with the industry’s 3.6% yield. The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.4%.